http://www.cnr.it/ontology/cnr/individuo/prodotto/ID109197

Adiponectin and cardiometabolic risk factor: effect on myocardial blood flow in patients with dilated cardiomyopathy (Abstract/Comunicazione in atti di convegno)

Type

Abstract/Comunicazione in atti di convegno (Classe)
Prodotto della ricerca (Classe)

Label

Adiponectin and cardiometabolic risk factor: effect on myocardial blood flow in patients with dilated cardiomyopathy (Abstract/Comunicazione in atti di convegno) (literal)

Anno

2010-01-01T00:00:00+01:00 (literal)

Alternative label

Caselli C.; Cabiati M.; Prescimone T.; Del Ry S.; Pardini S.; Sampietro T.; L'Abbate A.; Giannessi D.; Neglia D. (2010)
Adiponectin and cardiometabolic risk factor: effect on myocardial blood flow in patients with dilated cardiomyopathy
in European Society of Cardiology Congress, Stockholm
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Caselli C.; Cabiati M.; Prescimone T.; Del Ry S.; Pardini S.; Sampietro T.; L'Abbate A.; Giannessi D.; Neglia D. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#note

In: ESC Congress - European Society of Cardiology Congress (Stockholm, 28 Aug - 01 Sept 2010). Abstract, vol. 31 pp. 788 - 788. European Heart Journal ( Abstract Supplement ), 2010. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#descrizioneSinteticaDelProdotto

Purpose: Adiponectin (ADN) is an insulin-sensitizing, anti-atherogenic and anti-inflammatory adipocytokine, with endothelial protective effects. In patients with dilated cardiomyopathy (DCM), absolute myocardial blood flow (MBF) is frequently impaired because of coronary microvascular/endothelial dysfunction. We aimed at evaluating whether the potential effects of ADN on MBF in DCM are modulated by cardiometabolic risk factors. Methods: Sixty-one consecutive patients (46 males, age 59±10 yrs) with LV dysfunction (LV ejection fraction 38±9%, range 19-54%) and angiographically normal coronary arteries were studied. Absolute MBF was measured by positron emission tomography, using 13N-Ammonia as flow tracer, both at rest and during dipyridamole infusion (0.56 mg/kg I.V. over 4 min). Abnormal MBF was defined for resting MBF0.65 ml/min/g and dipyridamole MBF1.36 ml/min/g. Plasma adiponectin was measured by a specific ELISA (Linco Research). Cardiometabolic risk factors including age, sex, insulin resistance, lipid profile and obesity were entered into a multivariate linear regression analysis to assess independent determinants of adiponectin and, in turn, their effect on myocardial and microvascular damage. Results: Abnormal MBF was present in 34/61 patients, in 13/31 (42%) with ADN higher than median value and in 21/30 (70%) with ADN levels lower than median value (p0.05). Among cardiometabolic risk factors, only HDL-cholesterol and obesity were independent determinants of ADN [0.34 (0.13), -0.34 (0.14), ²-coefficient (SE), respectively, p0.05] at multivariate analysis. After correction for HDL-cholesterol and obesity the positive association between ADN and MBF remained significant (p0.05). Conclusion: ADN is a determinant of MBF in DCM patients and is related with low HDL-cholesterol and obesity. (literal)

Note

ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

CNR-IFC, Pisa, Scuola Superiore Sant'Anna, Pisa (Italy), Sector of Medicine, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy, Scuola Superiore S. Anna, Pisa, Italy (literal)

Titolo